Guerbet is publishing revenue of €407.1 million for the 1st half-year of 2017, up 8.1% at current exchange rates and 5.6% at constant exchange rates (CER). In the second quarter, published revenue stood at €204.0 million, up 5.7% at current exchange rates and 3.8% at CER.
Guerbet announced today that it will phase out sales throughout the world of two products: Hexabrix® (meglumine and sodium ioxaglate) and Optimark® (gadoversetamide).
22/06/2017 MLCTO 2017: Guerbet, a partner in the initiatives implemented for interventional cardiologists
MLCTO 2017 │ from June 29 to July 1 │ Hyatt Regency │ Palais de la Méditerranée │ Nice (France)
APPLE 2017 │ from July 14 to 16 │ Grand Copthorne Waterfront Hotel │ Singapore
14/06/2017 Guerbet invests in the Truffle Capital fund dedicated to medical devices and biotechnologies
Guerbet today announced that it has signed an equity acquisition of fifteen million Euros in the BioMedTech fund (FPCI) managed by Truffle Capital
ESGAR 2017 │ from June 20 to 23 │ Megaron Athens International Conference Centre │ Athens (Greece)
GEST 2017 │ Stand No. 12 │ from May 31 to June 3 │ Firenze Fiera Congress and Exhibition Centre│ Florence (Italy)